Op-Ed By: Stacy Snow Feiler — former President and co-founder of Liberty Tree Consulting, a Public Policy and Grassroots Advocacy Firm
America’s obesity crisis is real. So is the extraordinary promise of GLP-1 medications such as semaglutide and tirzepatide. These drugs are changing lives, reducing obesity-related disease, and offering millions of Americans a path toward better health. But alongside this medical breakthrough, another market has exploded — one that operates in the shadows of weak enforcement, regulatory ambiguity, and dangerous foreign sourcing.
That market is the sprawling trade in compounded and quasi-compounded GLP-1 products made with illicit, unregulated, or potentially unsafe active pharmaceutical ingredients (APIs), many sourced overseas from facilities with questionable quality controls. And while legitimate access programs like TrumpRX attempt to expand availability of FDA-approved medications at lower prices, the FDA’s sluggish enforcement posture has allowed a parallel economy of copycat products to thrive.
The result is a public-health contradiction: Washington claims to prioritize safe access to weight-loss therapies while simultaneously tolerating a marketplace flooded with products that may not meet basic standards for sterility, potency, purity, or consistency.
The FDA’s defenders argue that the agency has issued warning letters and proposed new rules. That is true — on paper. But the facts on the ground tell a different story. The gray market remains enormous, online vendors continue operating openly, and compounded GLP-1s remain widely available despite the official resolution of the branded drug shortages that initially justified emergency compounding.
The core problem is not traditional pharmacy compounding for individual patients with unique clinical needs. Legitimate compounding has long served an important medical purpose. The problem is industrial-scale manufacturing masquerading as individualized medicine while relying on imported APIs from opaque supply chains that regulators often struggle to monitor effectively.
According to reporting and regulatory reviews, some of these APIs have been sourced from foreign facilities that were never properly registered or adequately inspected. Others were marketed explicitly as “research use only” while simultaneously being sold into human consumption channels. Reuters reported that the FDA issued warning letters to several companies selling unapproved semaglutide and tirzepatide products under the guise of research compounds intended “not for human consumption.” Yet regulators found clear evidence these products were in fact being marketed for human use.
This is not a hypothetical risk. It is an active supply-chain vulnerability involving injectable drugs that consumers place directly into their bodies.
The concerns become even more alarming when examining inspection findings tied to some foreign API suppliers. Records cited in public reporting described contamination concerns ranging from residue on supposedly clean equipment to water leaks, insect presence, and sterile-process deficiencies. These are not minor paperwork violations. Sterile injectable medications demand extraordinary manufacturing precision because contamination failures can lead to severe illness, hospitalization, or worse.
The FDA itself has documented adverse events associated with compounded GLP-1 products, including dosing mistakes and the use of semaglutide salt forms that have not been demonstrated to be safe or effective.
Yet despite these documented concerns, enforcement lagged behind the explosion in demand.
That delay matters because consumers are rational actors responding to price signals. When FDA-approved GLP-1 therapies remained financially out of reach for many Americans, a vacuum emerged. Compounders and gray-market operators rushed to fill it. Some acted responsibly. Others clearly did not.
What should trouble policymakers most is how sophisticated this marketplace has become. These products are not being sold from dark alleyways or obvious scam websites. They are promoted through polished telehealth campaigns, influencer marketing, targeted social media advertising, and direct-to-consumer subscription models designed to appear mainstream and medically legitimate.
Meanwhile, online communities openly discuss sourcing raw ingredients from China, self-mixing formulations at home, and trading dosing advice peer-to-peer because approved products remain expensive or inaccessible. Reuters documented Americans purchasing bulk GLP-1 ingredients online and essentially becoming their own pharmacist, regulator, and dosing specialist.
That is not healthcare modernization. It is regulatory failure.
This is where the TrumpRX issue becomes politically and operationally significant.
TrumpRX was designed around a simple premise: negotiate lower prices for legitimate FDA-approved medications and make them accessible to consumers who lack adequate insurance coverage. According to reporting, the platform achieved substantial reductions in GLP-1 pricing, bringing monthly costs dramatically below prior list prices.
But any price-reduction strategy collapses if regulators simultaneously allow unsafe or unapproved alternatives to undercut those prices even further.
Consumers comparing costs alone will inevitably drift toward the cheapest option, particularly when slick marketing obscures the distinction between FDA-approved therapies and compounded knockoffs. The FDA’s delayed enforcement effectively handicapped TrumpRX before it could fully establish itself as the trusted lower-cost alternative.
That is the central policy failure.
The federal government cannot credibly encourage consumers toward regulated pharmaceutical channels while tolerating a competing ecosystem built around legal loopholes and inconsistent oversight. Every month enforcement stalled gave gray-market suppliers additional time to acquire customers, normalize their products, and entrench themselves within the digital healthcare economy.
And once these markets mature, shutting them down becomes exponentially harder.
Supporters of the FDA point to warning letters, proposed exclusions from the 503B bulks list, and promises of future crackdowns. But promises are not enforcement. Even recent online discussions among compounding-industry observers reflect the widespread perception that the FDA moved slowly and inconsistently, allowing large-scale operations to continue long after shortages officially ended.
This inconsistency created the worst possible environment: enough enforcement rhetoric to generate confusion, but insufficient action to eliminate unsafe actors.
The consequences extend beyond obesity treatment alone. Public trust in pharmaceutical oversight depends on consumers believing that someone is actually guarding the gate. If Americans conclude that injectable medications of uncertain origin can circulate freely for years while regulators deliberate, confidence in the entire drug safety system erodes.
That erosion carries long-term implications for every therapeutic category.
The irony is that there was a viable alternative available. Rather than permitting the gray market to dominate affordability, regulators could have aggressively coordinated with legitimate access programs while simultaneously cracking down on illicit or noncompliant compounding operations. Faster enforcement combined with expanded access to approved products would have reduced consumer migration toward questionable alternatives.
Instead, the government pursued a half-measure approach that satisfied nobody.
Patients remained frustrated by costs. Legitimate pharmaceutical channels faced unfair competition from lower-cost compounded versions. Ethical compounders were lumped together with bad actors. And unsafe foreign API suppliers gained valuable time to feed a booming American demand surge.
None of this means every compounded GLP-1 product is inherently unsafe. That would be inaccurate and unfair. But the current system makes it extraordinarily difficult for consumers to distinguish between compliant pharmacies operating responsibly and opportunistic actors exploiting loopholes for profit.
When injectable drugs originate from poorly inspected overseas facilities or from suppliers operating in legal gray zones, the burden of risk shifts directly onto patients.
That is unacceptable.
The FDA exists precisely because pharmaceutical markets cannot function safely on caveat emptor alone. Consumers cannot independently verify sterile manufacturing conditions in foreign API plants. They cannot chemically validate purity standards in home laboratories. They cannot inspect global pharmaceutical supply chains before injecting a product into their bodies.
That is the regulator’s job.
And in the GLP-1 arena, regulators moved too slowly while the market evolved too quickly.
The obesity epidemic deserves serious solutions grounded in safety, affordability, and transparency. Programs like TrumpRX attempt to address affordability through legitimate channels. But those efforts lose effectiveness when regulators permit unregulated alternatives to proliferate unchecked for months or years.
The FDA should stop treating enforcement as a messaging exercise and start treating it as a public-health imperative. Unsafe APIs, counterfeit formulations, and industrial-scale loophole compounding are not victimless regulatory technicalities. They represent real risks attached to one of the fastest-growing drug categories in America.
The longer Washington delays decisive action, the more normalized this dangerous gray market becomes — and the harder it will be to restore consumer trust once something catastrophic inevitably goes wrong.
About the author:
Stacy Snow Feiler — former President and co-founder of Liberty Tree Consulting, a Public Policy and Grassroots Advocacy Firm
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
